Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
Marketing Status Prescription
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 68071-2051; 68071-2035; 51655-284; 68071-4984; 68071-5248; 70518-2472; 65162-705; 42708-023; 70518-1110; 0456-2010; 63187-281; 71610-425; 61919-652; 63187-217; 50090-3331; 16729-168; 55700-847; 69097-849; 45865-699; 76282-249; 71335-1002; 0456-2005; 43547-281; 67296-1421; 0615-8349; 68001-455; 70518-2597; 63629-8241; 70518-3151; 68071-4985; 67296-1200; 33342-053; 51655-449; 53002-1438; 70934-112; 70771-1146; 68788-7510; 68788-7559; 16729-170; 0615-8348; 70518-1876; 70518-2317; 43063-661; 70518-2430; 71335-1307; 43547-282; 50090-4915; 70771-1147; 55700-818; 0615-8366; 68001-456; 71335-1571; 16729-169; 69097-848; 71335-1187; 70518-1805; 70518-1785; 67296-1689; 68645-520; 60760-393; 53002-2438; 50090-4363; 76282-251; 71205-344; 71335-1241; 50090-1930; 60760-170; 0615-8365; 68788-7461; 42708-022; 72789-194; 54838-551; 76282-250; 68788-7912; 0456-2020; 69097-847; 68001-454; 68645-519; 50090-5312; 67296-1597; 71205-325; 53002-1453; 43547-280; 71335-1030; 0615-8350; 68071-3069; 50090-2196; 67296-1408; 71610-534; 70771-1145; 71335-2058
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arthropod sting12.01.08.023--Not Available
Aspartate aminotransferase increased13.03.01.0060.000380%
Asphyxia22.02.02.001; 12.01.08.0110.000074%Not Available
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.0020.000095%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrial septal defect03.07.02.002; 02.04.02.0090.000818%Not Available
Atrioventricular block02.03.01.0020.000095%Not Available
Atrioventricular block complete02.03.01.0030.000142%
Atrioventricular block first degree02.03.01.0040.000190%
Atrioventricular block second degree02.03.01.0050.000095%
Atrophic vulvovaginitis21.02.01.003--Not Available
Attention deficit/hyperactivity disorder19.21.04.0010.000142%Not Available
Autism19.22.02.001; 17.03.05.0010.000095%Not Available
Autoimmune hepatitis09.01.07.019; 10.04.09.0010.000095%Not Available
Back injury12.01.09.002--Not Available
Back pain15.03.04.005--
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.0030.000095%Not Available
Benign breast neoplasm21.05.01.009; 16.14.01.005--Not Available
Bipolar I disorder19.16.01.0020.000142%Not Available
Bladder dilatation20.03.01.007--Not Available
Bladder discomfort20.02.02.019--Not Available
Bladder pain20.02.02.001--Not Available
Blepharospasm17.17.02.001; 06.05.01.0010.000285%Not Available
Blindness06.02.02.001; 17.17.01.003--Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.000190%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.01.008--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 38 Pages